Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Nováček

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Chemical Theory and Computation|January 3, 2025
PM6-ML: The Synergy of Semiempirical Quantum Chemistry and Machine Learning Transformed into a Practical Computational MethodMartin Nováček, Jan Řezáč
The Journal of Chemical Physics|May 22, 2024
Working with benchmark datasets in the Cuby frameworkJan Řezáč, Outi Vilhelmiina Kontkanen, Martin Nováček
Journal of Chemical Theory and Computation|February 23, 2021
Non-Covalent Interactions Atlas Benchmark Data Sets 3: Repulsive ContactsKristian Kříž, Martin Nováček, Jan Řezáč
Neuro Endocrinology Letters|December 22, 2023
Loss of Consciousness and Prolonged Convulsions Due to Amanita Pantherina IntoxicationLukáš Handl, Martin Nováček, Robin Šín, et al.
Critical Care (London, England)|August 12, 2021
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trialJean-François Timsit, Jennifer A Huntington, Richard G Wunderink, et al.
The Lancet. Infectious Diseases|September 30, 2019
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trialMarin H Kollef, Martin Nováček, Ülo Kivistik, et al.
The Journal of Antimicrobial Chemotherapy|January 13, 2022
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumoniaIgnacio Martin-Loeches, Jean-François Timsit, Marin H Kollef, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Chemical Theory and Computation|January 3, 2025
PM6-ML: The Synergy of Semiempirical Quantum Chemistry and Machine Learning Transformed into a Practical Computational MethodMartin Nováček, Jan Řezáč
The Journal of Chemical Physics|May 22, 2024
Working with benchmark datasets in the Cuby frameworkJan Řezáč, Outi Vilhelmiina Kontkanen, Martin Nováček
Journal of Chemical Theory and Computation|February 23, 2021
Non-Covalent Interactions Atlas Benchmark Data Sets 3: Repulsive ContactsKristian Kříž, Martin Nováček, Jan Řezáč
Neuro Endocrinology Letters|December 22, 2023
Loss of Consciousness and Prolonged Convulsions Due to Amanita Pantherina IntoxicationLukáš Handl, Martin Nováček, Robin Šín, et al.
Critical Care (London, England)|August 12, 2021
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trialJean-François Timsit, Jennifer A Huntington, Richard G Wunderink, et al.
The Lancet. Infectious Diseases|September 30, 2019
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trialMarin H Kollef, Martin Nováček, Ülo Kivistik, et al.
The Journal of Antimicrobial Chemotherapy|January 13, 2022
Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumoniaIgnacio Martin-Loeches, Jean-François Timsit, Marin H Kollef, et al.
Pageof 1